NCT07535632 2026-04-17
BEST
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
Clinical Trials
38 trialsNCT07527832 2026-04-14
An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan.
Pfizer
Not yet recruiting
NCT07525206 2026-04-13
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
AbbVie
Phase 3 Not yet recruiting
NCT07500298 2026-03-30
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07474727 2026-03-16
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
Multitude Therapeutics Inc.
Phase 2 Not yet recruiting
NCT07318389 2026-02-27
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Not yet recruiting
NCT07395063 2026-02-09
A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 2 Not yet recruiting
NCT07391566 2026-02-06
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
Luye Pharma Group Ltd.
Phase 1/2 Not yet recruiting
NCT07381764 2026-02-02
ROMANCE - GOIM
Gruppo Oncologico Italia Meridionale
Phase 2 Not yet recruiting
NCT07359456 2026-01-22
COLIBRI-GI
UNICANCER
Phase 2 Not yet recruiting
NCT07094893 2026-01-14
ARIEL-ENGIC
Gruppo Oncologico del Nord-Ovest
Phase 4 Not yet recruiting
NCT07337551 2026-01-13
Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive
The Second Hospital of Hebei Medical University
Phase 2 Not yet recruiting
NCT07229846 2026-01-08
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
Harbin Medical University
Phase 2 Not yet recruiting
NCT07271355 2025-12-09
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
City of Hope Medical Center
Phase 3 Not yet recruiting
NCT07261709 2025-12-03
Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07150403 2025-09-08
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2 Not yet recruiting
NCT07134101 2025-08-29
SMARTi-RC01
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT07123441 2025-08-14
A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer
Fudan University
Phase 2 Not yet recruiting
NCT07106034 2025-08-12
ONTOP
Shanghai Pudong Hospital
Phase 2 Not yet recruiting
NCT07071844 2025-07-17
BETWEEN
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Not yet recruiting
NCT07025239 2025-06-17
QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07021950 2025-06-15
AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07007728 2025-06-06
Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT07009145 2025-06-06
QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC
Qianfoshan Hospital
Phase 2 Not yet recruiting
NCT06882915 2025-03-19
Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Not yet recruiting
NCT06858956 2025-03-05
Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not yet recruiting
NCT06835179 2025-02-19
SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06341309 2024-08-09
Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer
West China Hospital
Phase 1/2 Not yet recruiting
NCT06513221 2024-07-22
A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab
Fudan University
Phase 2 Not yet recruiting
NCT06434090 2024-05-30
Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT06415851 2024-05-16
Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab
Sir Run Run Shaw Hospital
Phase 2 Not yet recruiting
NCT06373133 2024-04-18
SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer
West China Hospital
Phase 1/2 Not yet recruiting
NCT06363552 2024-04-12
A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06192680 2024-01-18
Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer
Harbin Medical University
Phase 2 Not yet recruiting
NCT06195670 2024-01-08
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC
Zhejiang Cancer Hospital
Phase 1/2 Not yet recruiting
NCT06092242 2023-10-23
The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer
The Second Affiliated Hospital of Shandong First Medical University
Phase 2 Not yet recruiting
NCT05354674 2023-07-13
Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis
Fudan University
Not yet recruiting
NCT04831528 2021-04-05
Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study
Fudan University
Not yet recruiting